Sex | Age at diagnosis (years) | Hormonal function | Stage at diagnosis | Sites of metastatic disease at initiation of LEN/PEM | Genetic findings | |
1 | M | 37 | No | IV | Lungs, liver, bone | PTEN and CDKN2B mutations |
2 | F | 22 | No | III | Lung | No mutations |
3 | F | 21 | Yes | II | Lung, liver, adrenal bed | TP53 mutation (germline) |
4 | M | 39 | No | IV | Liver, lung, retroperitoneum, and bone | No mutations |
5 | M | 44 | Yes | IV | Lung | CDK4, MDM2, and CCND3 mutations |
6 | M | 34 | Yes | II | Lung, abdomen, and liver | CTNNB1 and TP53 mutation (germline) |
7 | F | 41 | No | III | Lung, abdomen, pelvis, and liver | CTNNB1, ATRX, MUTYH, and RB1 mutations |
8 | F | 49 | No | II | Lung, abdomen, and liver | No mutations |
LEN, lenvatinib; PEM, pembrolizumab.